View Entire Collection
By Clinical Topic
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
WEDNESDAY, Sept. 28 (HealthDay News) -- Disease-modifying anti-rheumatic drugs (DMARDs) may be more effective than ibuprofen or steroids in controlling juvenile idiopathic arthritis (JIA), but there is little strong evidence to support their long-term use, according to a new report released by the U.S. Department of Health and Human Service's Agency for Healthcare Research and Quality (AHRQ).
Members of the Duke Evidence-based Practice Center evaluated data on JIA treatment options to compare DMARDs to conventional therapies, to compare various DMARDs with each other, and to evaluate tools used to measure clinical outcomes associated with the condition.
The researchers found that DMARDs have improved health outcomes for children with JIA, but that there are not enough data to compare DMARDS or classes of DMARDS. They also note that the tools currently available may not be able to accurately and sensitively capture and describe disease status.
"The pain associated with juvenile arthritis can be debilitating and even excruciating for young patients and is a major concern for both patients and their families," AHRQ director Carolyn M. Clancy, M.D., said in a statement. "Until a cure for juvenile arthritis is found, patients want the best, safest treatment to relieve that pain. This report will help patients choose the right treatment together with their clinician."
Find in-depth content on major issues provided by leading companies in partnership with NursingCenter.com
BD Safety Beyond Needlestick Prevention Learning Center
Sponsored by BD Medical
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top